Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02699333 · ClinicalTrials.gov registry record
Risk Factors for Microscopic Colitis
A clinical trial of Colitis, Microscopic, sponsored by University of North Carolina, Chapel Hill.
- Completed
- Registry status
- 346
- Enrollment target
- 1
- Study location
NCT02699333: Completed study of Colitis, Microscopic, sponsored by University of North Carolina, Chapel Hill.
NCT02699333 is a study of Colitis, Microscopic that has completed, run by University of North Carolina, Chapel Hill. The registered enrollment target is 346 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02699333, a study of Colitis, Microscopic, has completed, sponsored by University of North Carolina, Chapel Hill.
- COMPLETED
- Registry status
- 346 participants
- Enrollment target
- 1
- Study location
Study Summary
Microscopic colitis is a common cause of watery diarrhea, particularly in the elderly. Although the incidence is comparable to ulcerative colitis and Crohn's disease, the etiology is unknown. Understanding the etiology of microscopic colitis is an important step in developing logical interventions to decrease the burden from microscopic colitis. This research could provide critical insights into the etiology of this poorly studied condition.
Primary Outcome
Microscopic colitis defined by increased lymphocytes or collagen
Conditions Studied
Study Locations (1)
North Carolina
- University of North Carolina - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 346 participants |
| Start Date | 2016-05-01 |
| Est. Completion | 2020-12-24 |
What the finished NCT02699333 record still lists
NCT02699333 is an observational study that tracks outcomes without assigning an intervention. The registered 346 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Colitis, Microscopic appearing as the primary indexed condition, and to 0 interventions.
NCT02699333 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02699333 about?
NCT02699333 is a clinical study titled "Risk Factors for Microscopic Colitis". Microscopic colitis is a common cause of watery diarrhea, particularly in the elderly. Although the incidence is comparable to ulcerative colitis and Crohn's disease, the etiology is unknown. Understanding the etiology of microscopic colitis is an important step in developing logical interventions t...
What is the current status of trial NCT02699333?
This trial is currently completed. The enrollment target is 346 participants. The study started on 2016-05-01. Estimated completion is 2020-12-24.
What conditions does trial NCT02699333 study?
This clinical trial studies the following conditions: Colitis, Microscopic.
Who is sponsoring clinical trial NCT02699333?
This trial is sponsored by University of North Carolina, Chapel Hill, which has 1,109 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02699333 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267886 · 346 participants · Phase 4
CAPITAL DOREMI 2: Inotrope Versus Placebo Therapy for Cardiogenic Shock
- NCT06705842 · 346 participants · Phase 4
APPI-Cost Trial for Perforated Appendicitis
- NCT06932887 · 346 participants · Phase 3
The Beat Pain Better Trial
- NCT01742143 · 347 participants
Impact of ICCAN on Cancer Treatment Completion and Quality of Life
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI